Pembrolizumab + Favezelimab + Favezelimab/Pembrolizumab + Vibostolimab + Pembrolizumab/Vibostolimab
Phase 1/2Withdrawn 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neoplasm Metastasis
Conditions
Neoplasm Metastasis
Trial Timeline
Jan 15, 2025 → Jun 30, 2029
NCT ID
NCT06395090About Pembrolizumab + Favezelimab + Favezelimab/Pembrolizumab + Vibostolimab + Pembrolizumab/Vibostolimab
Pembrolizumab + Favezelimab + Favezelimab/Pembrolizumab + Vibostolimab + Pembrolizumab/Vibostolimab is a phase 1/2 stage product being developed by Merck for Neoplasm Metastasis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06395090. Target conditions include Neoplasm Metastasis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06395090 | Phase 1/2 | Withdrawn |
Competing Products
20 competing products in Neoplasm Metastasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AB0024 | Gilead Sciences | Phase 1 | 32 |
| TTI-237 | Pfizer | Phase 1 | 32 |
| 852A | Pfizer | Phase 1 | 32 |
| EO-3021 + Ramucirumab (CYRAMZA®) + Dostarlimab | CSPC Pharmaceutical Group Limited | Phase 1 | 32 |
| LY2780301 | Eli Lilly | Phase 1 | 33 |
| Pemetrexed | Eli Lilly | Phase 2 | 52 |
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 41 |
| IMC-3C5 | Eli Lilly | Phase 1 | 33 |
| LY3295668 | Eli Lilly | Phase 1/2 | 41 |
| Abemaciclib + Clarithromycin | Eli Lilly | Phase 1 | 33 |
| Abemaciclib + Fulvestrant | Eli Lilly | Phase 2 | 52 |
| Galunisertib + Gemcitabine + Placebo | Eli Lilly | Phase 1/2 | 41 |
| Fulvestrant + Abemaciclib | Eli Lilly | Phase 2 | 52 |
| Abemaciclib + Fulvestrant + Placebo | Eli Lilly | Phase 3 | 77 |
| Prexasertib + Cisplatin + Cetuximab + G-CSF + Pemetrexed + Fluorouracil + LY3023414 + Leucovorin | Eli Lilly | Phase 1 | 33 |
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| Tadalafil + Gemcitabine | Eli Lilly | Phase 1 | 33 |
| enzastaurin | Eli Lilly | Phase 2 | 52 |
| enzastaurin + gemcitabine | Eli Lilly | Phase 2 | 52 |
| Abemaciclib + Darolutamide + LHRH agonist/antagonist | Eli Lilly | Phase 1 | 33 |